Please provide your email address to receive an email when new articles are posted on . Men with low- or intermediate-risk prostate cancer achieved similar quality-of-life outcomes whether they ...

WASHINGTON, September 30, 2024 — People with low- and intermediate-risk prostate cancer treated with either of two types of contemporary radiation therapy — proton beam therapy or intensity modulated ...

SAN FRANCISCO, September 29, 2025 — A new phase III clinical trial finds that intensity-modulated radiation therapy (IMRT) and proton beam therapy resulted in similar quality-of-life outcomes and low ...

The first randomized trial to compare proton therapy with conventional radiotherapy has not found a difference in toxicity, which is the main claim for superiority of proton therapy. The trial was ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Patient-reported quality of life (QoL) was similar between ...

Proton Therapy reduces the risk of a second cancer diagnosis by 69% versus other forms of radiation treatment according to a paper recently released by a team from Stanford University. The study ...

In the other study, Dr. Ciezki’s team used the Surveillance, Epidemiology, and End Results (SEER)-Medicare database to identify patients aged 65 years and older treated for PCa from 1991 to 2007. Of ...

NEW YORK (Reuters Health) - An expensive prostate cancer radiation treatment known as proton beam therapy has just as many side effects as a more common and cheaper radiation method, according to a ...

The big question about proton beam radiotherapy — is it any better than conventional radiotherapy? — is being addressed in seven ongoing randomized clinical trials sponsored by the National Cancer ...

Previously, results from the photon cohort of the NRG-BN001, a signal seeking Phase II randomized trial, indicated that photon radiation dose intensification (75 Gy) did not demonstrate improvement in ...

Proton beam therapy does not improve the patient-reported outcome of bowel function compared with IMRT. Bowel side effects do not differ between patients with localized prostate cancer who receive ...